A study to evaluate the effect of fluvoxamine, paroxetine, and smoking on a single IPN60170 (mesdopetam) dose in healthy male participants
- 09 October 2024 - 1 mins read
This study will investigate the pharmacokinetics (PK), safety, and tolerability of IPN60170 and its metabolites in smokers and nonsmokers healthy male participants. IPN60170 is being developed as a potential treatment to reduce levodopa-induced dyskinesia (LID) and psychosis in patients with Parkinson’s Disease (PD).
09 October 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
09 October 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
09 October 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
09 October 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
09 October 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
09 October 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
09 October 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
09 October 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
09 October 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
09 October 2024
1 mins read